Market Overview

Benzinga's Top Downgrades

Related ONXX
How to Prepare for the New Year
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen
Related GUID
Is Guidance Software's (GUID) Run to $10 Just the Beginning? - Tale of the Tape
UPDATE: Benchmark Company Upgrades Guidance Software on More Balanced Risk/Reward Profile

Analysts at Jefferies downgraded ONYX Pharmaceuticals (NASDAQ: ONXX) from “buy” to “hold.” The target price for ONYX Pharmaceuticals has been raised from $104 to $132. ONYX's shares closed at $134.40 yesterday.

Benchmark downgraded Guidance Software (NASDAQ: GUID) from “buy” to “sell.” The target price for Guidance Software has been lowered from $9 to $7. Guidance Software's shares closed at $9.53 yesterday.

Bank of America downgraded ViroPharma (NASDAQ: VPHM) from “buy” to “neutral.” The target price for ViroPharma is set to $34. ViroPharma's shares closed at $32.00 yesterday.

Analysts at Wunderlich downgraded United Stationers (NASDAQ: USTR) from “buy” to “hold.” The target price for United Stationers has been raised from $39 to $42. United Stationers' shares closed at $42.72 yesterday.

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Most Popular

Related Articles (GUID + ONXX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free